| Literature DB >> 26855668 |
Andreea-Teodora Pânzariu1, Maria Apotrosoaei1, Ioana Mirela Vasincu1, Maria Drăgan1, Sandra Constantin1, Frédéric Buron2, Sylvain Routier2, Lenuta Profire1, Cristina Tuchilus3.
Abstract
BACKGROUND: l-Arginine is a semi-essential aminoacid with important role in regulation of physiological processes in humans. It serves as precursor for the synthesis of proteins and is also substrate for different enzymes such as nitric oxide synthase. This amino-acid act as free radical scavenger, inhibits the activity of pro-oxidant enzymes and thus acts as an antioxidant and has also bactericidal effect against a broad spectrum of bacteria. <br> RESULTS: New thiazolidine-4-one derivatives of nitro-l-arginine methyl ester (NO2-Arg-OMe) have been synthesized and biologically evaluated in terms of antioxidant and antibacterial/antifungal activity. The structures of the synthesized compounds were confirmed by (1)H, (13)C NMR, Mass and IR spectral data. The antioxidant potential was investigated using in vitro methods based on ferric/phosphomolybdenum reducing antioxidant power and DPPH/ABTS radical scavenging assay. The antibacterial effect was investigated against Gram positive (Staphylococcus aureus ATCC 25923, Sarcina lutea ATCC 9341) and Gram negative (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853) bacterial strains. The antifungal activity was also investigated against Candida spp. (Candida albicans ATCC 10231, Candida glabrata ATCC MYA 2950, Candida parapsilosis ATCC 22019). <br> CONCLUSIONS: Synthesized compounds showed a good antioxidant activity in comparison with the NO2-Arg-OMe. The antimicrobial results support the selectivity of tested compounds especially on P. aeruginosa as bacterial strain and C. parapsilosis as fungal strain. The most proper compounds were 6g (R = 3-OCH3) and 6h (R = 2-OCH3) which showed a high free radical (DPPH, ABTS) scavenging ability and 6j (R = 2-NO2) that was the most active on both bacterial and fungal strains and also it showed the highest ABTS radical scavenging ability.Graphical abstract1: ethyl 3-aminopropionate hydrochloride, 2a-j: aromatic aldehydes, 3: thioglycolic acid, 4a-j: thiazolidine-propionic acid derivatives , 5: Nω-nitro-L-arginine methyl ester hydrochloride, 6a-j: thiazolidine-propionyl-nitro-L-arginine methyl ester derivatives.Entities:
Keywords: 1,3-Thiazolidine-4-one; Antibacterial/antifungal activity; Antioxidant effects; Nitro-l-arginine methyl ester; Spectral methods
Year: 2016 PMID: 26855668 PMCID: PMC4743259 DOI: 10.1186/s13065-016-0151-6
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Scheme 1Synthesis of compounds 6a–j. Reagents and conditions: a DIPEA, toluene, reflux 24–30 h; b KOH 1 M, EtOH/THF (1/1), r.t. 8–12 h then HCl 1 M; c N -nitro-l-arginine methyl ester hydrochloride (5), HOBt, EDC, DCM, r.t. 10–15 h
Synthesis of derivatives 4 and 6
| Entry | Comp. | R |
|
|
|---|---|---|---|---|
| 1 |
| H | 73 | 93 |
| 2 |
| 4-CH3 | 55 | 91 |
| 3 |
| 4-Cl | 59 | 89 |
| 4 |
| 4-F | 67 | 75 |
| 5 |
| 4-Br | 78 | 87 |
| 6 |
| 4-OCH3 | 55 | 86 |
| 7 |
| 3-OCH3 | 57 | 78 |
| 8 |
| 2-OCH3 | 64 | 76 |
| 9 |
| 3-NO2 | 63 | 50 |
| 10 |
| 2-NO2 | 82 | 91 |
aYields are indicated in isolated compounds
Fig. 1The DPPH radical scavenging ability (%) of derivatives 6a–j
The DPPH scavenging ability (EC50 mg/mL) of derivatives 6a–j
| Compound | EC50 (mg/mL) | Compound | EC50 (mg/mL) |
|---|---|---|---|
|
| 1.7294 ± 0.048 |
| 1.8869 ± 0.013 |
|
| 2.5980 ± 0.013 |
| 1.8068 ± 0.028 |
|
| 2.5354 ± 0.021 |
| 2.7992 ± 0.012 |
|
| 2.6176 ± 0.012 |
| 2.8034 ± 0.014 |
|
| 2.2430 ± 0.032 |
| 2.7163 ± 0.019 |
|
| 2.4751 ± 0.015 |
| 2.8157 ± 0.017 |
|
| 0.0018 ± 0.008 |
Data are mean ± SD (n = 3, p < 0.05)
Fig. 2The ABTS radical scavenging ability (%) of derivatives 6a–j
The ABTS scavenging ability (EC50 mg/mL) of derivatives 6a–j
| Compound | EC50 (mg/mL) | Compound | EC50 (mg/mL) |
|---|---|---|---|
|
| 0.4699 ± 0.013 |
| 0.0827 ± 0.017 |
|
| 0.4967 ± 0.015 |
| 0.0918 ± 0.032 |
|
| 0.1885 ± 0.014 |
| 0.9434 ± 0.018 |
|
| 0.1720 ± 0.018 |
| 0.0525 ± 0.015 |
|
| 0.5954 ± 0.029 |
| 1.8487 ± 0.026 |
|
| 0.4182 ± 0.012 |
| 2.0574 ± 0.011 |
|
| 0.0075 ± 0.008 |
Data are mean ± SD (n = 3, p < 0.05)
Fig. 3The absorbance of derivatives 6a–j in reference with NO2-Arg-OMe
The phosphomolydenum reducing antioxidant power (EC50 mg/mL) of 6a–j derivatives
| Compound | EC50 (mg/mL) | Compound | EC50 (mg/mL) |
|---|---|---|---|
|
| 1.6235 ± 0.015 |
| 2.7332 ± 0.037 |
|
| 2.0679 ± 0.018 |
| 3.5186 ± 0.018 |
|
| 2.0734 ± 0.022 |
| 2.1837 ± 0.024 |
|
| 2.1706 ± 0.014 |
| 2.4610 ± 0.019 |
|
| 0.6405 ± 0.012 |
| 2.6169 ± 0.032 |
|
| 2.3827 ± 0.013 |
| 2.7534 ± 0.006 |
|
| 0.0385 ± 0.001 |
Data are mean ± SD (n = 3, p < 0.05)
Fig. 4The absorbance of derivatives 6a–j in reference with NO2-Arg-OMe
The ferric reducing antioxidant power (EC50, mg/mL) of 6a–j
| Compound | EC50 (mg/mL) | Compound | EC50 (mg/mL) |
|---|---|---|---|
|
| 7.1876 ± 0.038 |
| 4.6474 ± 0.018 |
|
| 9.0695 ± 0.015 |
| 7.9317 ± 0.023 |
|
| 3.2742 ± 0.019 |
| 4.5202 ± 0.014 |
|
| 8.9671 ± 0.023 |
| 7.3504 ± 0.011 |
|
| 2.5781 ± 0.012 |
| 11.0778 ± 0.016 |
|
| 6.1302 ± 0.032 |
| 10.9321 ± 0.015 |
|
| 0.0109 ± 0.003 |
Data are mean ± SD (n = 3, p < 0.05)
Antibacterial/antifungal inhibition area (mm) of 6a–j derivatives
| Sample | Diameter of inhibition areaa (mm) | ||||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| SA | SL | EC | PA | CA | CG | CP | |
|
| 15.2 ± 0.12 | 19.3 ± 0.15 | 10.1 ± 0.06 | 13.1 ± 0.24 | 11.8 ± 0.35 | 15.2 ± 0.28 | 23.0 ± 0.19 |
|
| 14.1 ± 0.08 | 20.1 ± 0.13 | 15.1 ± 0.23 | 11.2 ± 0.41 | 12.9 ± 0.06 | 15.2 ± 0.98 | 24.1 ± 0.65 |
|
| 15.2 ± 0.16 | 18.1 ± 0.78 | 11.2 ± 0.63 | 11.9 ± 0.09 | 9.9 ± 0.62 | 13.8 ± 0.07 | 21.2 ± 0.33 |
|
| 15.3 ± 0.68 | 18.2 ± 0.55 | 10.2 ± 0.37 | – | 13.2 ± 0.21 | 16.4 ± 0.78 | 24.2 ± 0.35 |
|
| 12.1 ± 0.09 | 20.1 ± 0.43 | 10.1 ± 0.32 | 11.1 ± 0.19 | 12.1 ± 0.58 | 15.9 ± 0.55 | 25.3 ± 0.28 |
|
| 15.2 ± 0.52 | 20.1 ± 0.26 | 12.2 ± 1.05 | 10.2 ± 0.36 | 12.1 ± 0.18 | 15.5 ± 0.48 | 25.1 ± 0.37 |
|
| 13.1 ± 0.15 | 20.1 ± 0.72 | – | 10.1 ± 0.09 | 12.1 ± 0.28 | 15.9 ± 1.07 | 25.2 ± 0.39 |
|
| 14.1 ± 0.09 | 20.3 ± 0.43 | 11.1 ± 0.30 | 10.2 ± 0.15 | 12.1 ± 0.86 | 13.8 ± 0.57 | 23.1 ± 0.22 |
|
| 12.3 ± 0.08 | 21.1 ± 0.13 | 10.1 ± 0.23 | 12.2 ± 0.41 | 15.4 ± 0.06 | 16.4 ± 0.98 | 20.1 ± 0.65 |
|
| 16.3 ± 0.34 | 21.2 ± 0.87 | 10.2 ± 0.51 | 13.1 ± 0.82 | 15.2 ± 0.74 | 15.2 ± 0.32 | 23.1 ± 0.47 |
|
| 14.9 ± 0.16 | 19.9 ± 0.12 | 11.9 ± 0.06 | 11.8 ± 0.19 | 13.8 ± 0.15 | 15.9 ± 0.17 | 19.9 ± 0.09 |
|
| 20.1 ± 0.57 | 21.2 ± 1.16 | 15.2 ± 0.67 | – | – | – | – |
|
| 16.3 ± 0.28 | 30.4 ± 0.35 | 20.1 ± 0.16 | – | – | – | – |
|
| – | – | – | – | 19.4 ± 0.51 | 19.5 ± 0.72 | 12.4 ± 0.42 |
SA = Staphylococcus aureus ATCC 25923; SL = Sarcina lutea ATCC 9341; EC = Escherichia coli ATCC 25922; PA = Pseudomonas aeruginosa ATCC 27853; CA = Candida albicans ATCC 10231; CG = Candida glabrata ATCC MYA 2950; CP = Candida parapsilosis ATCC 22019; 5 = NO2-Arg-OMe; A = ampicillin; C = chloramphenicol; N = nystatin. 5 = L-NO2-Arg-OMe
aMean values (n = 3) ± standard deviation
Antibacterial effect expressed as MIC and MBC values (mg/mL) of 6a–j
| Sample |
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
| MICa | MBCa | MICa | MBCa | MICa | MBCa | MICa | MBCa | |
|
| 2.5 | 2.5 | 0.01 | 0.01 | 1.25 | 1.25 | 2.5 | 2.5 |
|
| 1.25 | 2.5 | 0.03 | 1.25 | 2.5 | 10 | 2,5 | 10 |
|
| 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.03 | 5 | 5 |
|
| 2.5 | 2.5 | 0.01 | 0.03 | 1.25 | 5 | 1.25 | 1.25 |
|
| 0.01 | 0.3 | 0.01 | 0.01 | 10 | 5 | 5 | 5 |
|
| 0.07 | 2.5 | 0.03 | 0.15 | 0.03 | 0.15 | 0.03 | 1.25 |
|
| 2.5 | 2.5 | 0.03 | 1.25 | 1.25 | 1.25 | 2.5 | 10 |
|
| 2.5 | 2.5 | 0.01 | 0.01 | 1.25 | 5 | 2.5 | 2.5 |
|
| 0.3 | 0.3 | 0.01 | 0.01 | 0.1 | 0.1 | 0.03 | 0.6 |
|
| 0.07 | 0.07 | 0.01 | 0.01 | 0.03 | 0.03 | 1.25 | 1.25 |
|
| 2.5 | 2.5 | 0.01 | 0.01 | 1.25 | 1.25 | 1.25 | 1.25 |
|
| 0.0002 | 0.0005 | 0.0002 | 0.0005 | 0.008 | 0.016 | nt | nt |
|
| 0.008 | 0.016 | 0.003 | 0.006 | 0.008 | 0.016 | nt | nt |
5 = L-NO2-Arg-OMe, A = ampicillin; C = chloramphenicol; nt = no tested
aMean values (n = 3) ± standard deviation
Antifungal effect expressed as MIC and MFC values (mg/mL) of 6a–j
| Sample |
|
|
| |||
|---|---|---|---|---|---|---|
| MICa | MFCa | MICa | MFCa | MICa | MFCa | |
|
| 0.6 | 1.25 | 1.25 | 1.25 | 0.003 | 0.003 |
|
| 0.6 | 1.25 | 2.5 | 10 | 0.003 | 0.003 |
|
| 0.6 | 0.6 | 10 | 10 | 0.003 | 0.003 |
|
| 0.3 | 1.25 | 0.6 | 2.5 | 0.003 | 0.003 |
|
| 10 | 10 | 10 | 10 | 5 | 5 |
|
| 0.6 | 0.6 | 2.5 | 5 | 0.003 | 0.003 |
|
| 0.3 | 1.25 | 1.25 | 2.5 | 0.003 | 0.003 |
|
| 0.3 | 5 | 10 | 10 | 0.003 | 0.003 |
|
| 0.03 | 10 | 10 | 10 | 10 | 10 |
|
| 0.3 | 1.25 | 1.25 | 1.25 | 0.003 | 0.003 |
|
| 1.25 | 1.25 | 0.6 | 2.5 | 0.003 | 0.003 |
|
| 0.004 | 0.008 | 0.004 | 0.008 | 0.004 | 0.008 |
5 = -L-NO2-Arg-OMe, N = nystatin
aMean values (n = 3) ± standard deviation